Personalis, Inc. reposted this
"Using #genome information, Bay Area-based Personalis, Inc. created a blood test that detected evidence of breast #cancer tumors up to 15 months earlier than traditional imaging." Following findings shared at #ASCO24, Personalis's Chief Medical Officer Dr. Richard Chen appeared on NBC Bay Area this week to highlight the success the company's Personal NeXT platform has seen in detecting early recurrence of #breastcancer
ICYMI: our Chief Medical Officer and Executive VP of R&D, Dr. Richard Chen, was featured on a local FOX KTVU2 News segment highlighting our whole-genome based, liquid biopsy assay, NeXT Personal®. NeXT Personal can detect very small traces of cancer from a blood test from patients with cancer and help predict relapse months, sometimes even years ahead of imaging. In a study from the The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust featuring 78 patients with early-stage breast cancer, 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Take a look at the segment that aired last month: https://bit.ly/4bOrkJE. #PrecisionOncology #ASCO24 #LiquidBiopsy #CancerResearch
Today, we announced that we entered into an agreement with Myriad Genetics to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps to solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. “Personalis has presented compelling clinical evidence across large lung cancer, breast cancer, and immunotherapy cohorts demonstrating the ability of its NeXT Personal® whole-genome-based MRD platform to drive a leap in performance for patients,” said Christopher Hall, CEO of Personalis. “We are excited to deepen our collaboration with Myriad by recognizing the importance of our respective patent estates in the field.” Learn more about this agreement: https://bit.ly/4eSgYLz #PrecisionOncology #MRD #CancerRecurrence #TherapyMonitoring #ctDNA
"Our focus is on individuals with a high risk of recurrence, where the value and impact of early detection justify the cost. As technology costs decrease, expanding to broader early detection becomes more feasible," says CEO of Personalis, Christopher Hall, in a special Newsweek report. See Chris’ thoughts about the future of life sciences and tackling cancer in the report, available now: https://bit.ly/4cUKZsd. #Cancer #PrecisionOncology
At #ASCO24 earlier this year, our collaborators presented impactful data highlighting NeXT Personal®, including two podium presentations! If you want to learn more about these data in breast cancer (in collaboration with The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust) and immunotherapy monitoring (in collaboration with Vall d'Hebron Institute of Oncology (VHIO)), check out our webinar with Endpoints News. In the breast cancer study with The Royal Marsden, NeXT Personal found that 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Watch the recording to learn more about the data presented at ASCO: https://bit.ly/4aUaRD7. #PrecisionOncology #Liquidbiopsy #BreastCancer #ctDNA #ImmunoTherapy
We’re honored to have recently celebrated our 5-year listing anniversary on NASDAQ! We’ve continuously been a leader in advanced genomics for cancer, and have strived to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. #PrecisionOncology #Genomics #NGS
Join us on Tuesday, June 18, from 1:00 pm - 2:00 pm EDT for a webinar highlighting new data in breast cancer and immunotherapy monitoring presented at ASCO 2024. In a breast cancer study with The Royal Marsden, NeXT Personal® found that 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Learn more about this study and other data from ASCO, including: - Immunotherapy treatment monitoring, pan-cancer with prognostic and predictive results - Therapy monitoring in patients with gastrointestinal (GI) cancers Some of our key partners and collaborators include The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Dana-Farber Cancer Institute, Duke Cancer Institute , and Vall d'Hebron Institute of Oncology (VHIO). Register today: https://bit.ly/4aUaRD7 #PrecisionOncology #Liquidbiopsy #BreastCancer #GastrointestinalCancer #ctDNA #ASCO24
Medical Billing and Coding Specialist with Account Management expertise
2wDoes this mean... you can take this blood test instead of mammogram screening? If so, this is a good alternative for patients who find that procedure physically and mentally taxing.